期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌术后辅助化疗:共识与争议 被引量：2

Consensus and Controversy for Adjuvant Chemotherapy in the Treatment of Breast Cancer
下载PDF
导出
摘要 乳腺癌是常见的恶性肿瘤之一，其发病率始终居高不下。但近30余年来，经全球100多项临床试验的证实，乳腺癌术后辅助化疗可以杀灭亚临床微小转移灶，从而降低乳腺癌患者术后复发率和死亡率。辅助化疗已经成为乳腺癌综合治疗方案中不可缺少的一部分．辅助化疗方案的建议和指南均建立在大型临床试验分析结果的基础上，研究者采取不同的化疗药物、剂量、周期、
作者 刘哲斌 邵志敏
机构地区 复旦大学附属肿瘤医院乳腺外科/乳腺癌研究所
出处 《循证医学》 CSCD 2009年第2期70-73,共4页 The Journal of Evidence-Based Medicine
关键词 乳腺肿瘤 治疗 辅助化疗 breast neoplasms treatment adjuvantchemotherapy
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Stewart BW, Kleihues P. World Cancer Report [M]. Geneva, Switzerland: World Health Organization, 2003.
  • 2Early Breat Cancer TrialistsI Collaborative Group (EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials [J]. Lancet, 2005,365(9742) : 1687-1717.
  • 3Early Breast Cancer Trlalists's Collaborative Group. Multi-agent chemotherapy for early breast cancer [DB/CD]. Cochrane Database Syst Rev, 2002, ( 1 ) : CD000487.
  • 4Poole CJ, Earl HM, Hiller L, et al. Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as adjuvant therapy for early breast cancer[J]. N Engl J Med, 2006,355 (18): 1851-1862.
  • 5Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive Cyclophosphamide, Epirubicin, and Fluorouraeil chemotherapy compared with Cyclophosphamide, Methotrexate, and Fluorouracil in premenopausal women with node-positive breast cancer[J]. J Clin Oncol, 1998,16(8):2651-2658.
  • 6Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer [J]. J Clin Oncol, 2003,21(6):976-983.
  • 7Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after Doxorubicin plus Cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28 [J ]. J Clin Oncol, 2005,23 (16) : 3686-3696.
  • 8Jones S, Holmes F, O'Shaughnessy J, et al. Extended follow- up and analysis by age of the US oncology adjuvant trial 9735 : Docetaxe[/Cyclophosphamide is associated with an OS benefit compared to Doxorubicin/Cyclophosphamide and is well- tolerated in women 65 or older. Paper presented at San Antonio Breast Cancer Symposium[C]. San Antonio, Texas, USA, 2007.
  • 9Jones SE, Savin MA, Holmes FA, et al. Phase Ⅲ trial comparing Doxorubicin plus Cyclophosphamide with Docetaxel plus Cyclophosphamide as adjuvant therapy for operable breast cancer [J]. J Clin Oncol, 2006,24(34):5381-5387.
  • 10Nabhohz JM, Pienkowski T, Mackey J, et al. Phase Ⅲ trial comparing TAC (Docetaxel, l)oxorubicin, Cyclophosphamide) with FAC (5-Fluorouracil, Doxorubicin, Cyclophosphamide) in adjuvant treatment of node positive breast cancer patients: Interim analysis of the BCIRG 001 study [J]. Pro Am Soc Clin Oncol, 2002,21 ( 1 ) : 36.

同被引文献7

引证文献2

二级引证文献4

循证医学
2009年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部